Oral Minoxidil Seasonal Use Considerations

What the seasonal hair study measured

The seasonal hair data come from a retrospective trichogram study published in Dermatology in 2009 [1]. Kunz and colleagues reviewed six years of records from 823 women who complained of hair loss and found annual periodicity in the proportion of hairs in each growth phase: the largest proportion of telogen (resting) hairs fell in summer, a smaller peak appeared in spring, and telogen rates were lowest in late winter [1]. A trichogram measures the share of hairs in each growth phase, not the total number of hairs on the scalp or the number of hairs shed per day, and these were women who sought help for hair loss.

What the oral minoxidil studies report

The oral minoxidil studies cited here report efficacy and safety for patients as a whole, not by season. A 2021 review collected 17 studies with 634 patients [5]. A 2025 meta-analysis reported blood pressure and heart rate changes with low-dose oral minoxidil [4]. A dose-response meta-regression of six studies in androgenetic alopecia found that each extra 1 mg/day was associated at six months with higher hair density (47.1 hairs/cm2) but also with a 17.9% higher risk of hypertrichosis and a 4.8% higher risk of cardiovascular adverse events; the authors describe these as associations, not causal findings [6].

What the low-dose numbers look like

A retrospective multicenter study followed 1404 patients treated with low-dose oral minoxidil for at least three months, with no control group [3]. Hypertrichosis occurred in 15.1% and led to withdrawal in 14 patients (0.5%); lightheadedness in 1.7%, fluid retention in 1.3%, and tachycardia in 0.9%. Systemic effects led to discontinuation in 29 patients (1.2%), and no life-threatening adverse effects were observed [3].

A 2025 meta-analysis of low-dose oral minoxidil at 5 mg/day or less found no significant change in systolic blood pressure (mean difference -0.13 mm Hg) or diastolic blood pressure (-1.25 mm Hg), but a significant rise in heart rate of 2.67 beats/min. Hypotensive symptoms were reported in 119 patients (5.0%), with no hypotensive episodes [4]. The included studies had no control groups [4].

What the oral tablet label says to watch for

• Minoxidil tablets carry a boxed warning: they can cause pericardial effusion, occasionally progressing to tamponade, and can worsen angina; they are reserved for hypertension that does not respond to maximum doses of a diuretic plus two other antihypertensives [2].
• The label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication [2].
• Hypertrichosis appears in about 80% of patients at antihypertensive doses, starting within 3 to 6 weeks at the temples, between the eyebrows and on the sideburns [2].
• Guanethidine is the only drug interaction named in the oral label, and combining the two can cause profound orthostatic hypotension [2].

Dose context

Oral minoxidil is used off-label for hair loss [2]. The tablet label starts hypertension treatment at 5 mg/day, with increases to 10, 20 and then 40 mg/day if needed [2]. A randomized trial in men with androgenetic alopecia used 5 mg/day [7], and another randomized trial used 1 mg/day [8]. None of the dosing described here is tied to a season.